(Z)-1,2-Diphenylethene

(Z)-1,2-Diphenylethene

SCHEMBL5588939

C(=Cc1ccccc1)c1ccccc1.C(=Cc1ccccc1)c1ccccc1.C(=Cc1ccccc1)c1ccccc1.[Ni]

nearest known ligand 0.69

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 0.69
NFE2L2 Q16236 4/20 0.63
CYP19A1 P11511 2/20 0.63
MAOA P21397 2/20 0.63
MEN1 O00255 1/20 0.60
KMT2A Q03164 1/20 0.60
CHAT P28329 2/20 0.57
TRPA1 O75762 3/20 0.55
ALDH1A1 P00352 1/20 0.55
LMNA P02545 1/20 0.55
ALOX5 P09917 1/20 0.55
MAPK1 P28482 1/20 0.55
RELA Q04206 2/20 0.55
CYP11B1 P15538 1/20 0.55
CYP11B2 P19099 1/20 0.55
HDAC3 O15379 1/20 0.52
TNKS O95271 1/20 0.52
HDAC4 P56524 1/20 0.52
HDAC1 Q13547 1/20 0.52
HCAR2 Q8TDS4 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
(Z)-1,2-Diphenylethene SCHEMBL11703942 1.00 MAOB (0.69) MAOBNFE2L2CYP19A1MAOAMEN1
(Z)-1,2-Diphenylethene SCHEMBL11602792 1.00 MAOB (0.69) MAOBNFE2L2CYP19A1MAOAMEN1
(Z)-1,2-Diphenylethene SCHEMBL347707 0.96 MAOB (0.73) MAOBNFE2L2CYP19A1MAOAMEN1
(Z)-1,2-Diphenylethene SCHEMBL21847984 0.96 MAOB (0.73) MAOBNFE2L2CYP19A1MAOAMEN1
(Z)-1,2-Diphenylethene SCHEMBL9488275 0.96 MAOB (0.73) MAOBNFE2L2CYP19A1MAOAMEN1
(Z)-1,2-Diphenylethene SCHEMBL443 0.96 MAOB (0.73) MAOBNFE2L2CYP19A1MAOAMEN1
(Z)-1,2-Diphenylethene SCHEMBL9134305 0.96 MAOB (0.73) MAOBNFE2L2CYP19A1MAOAMEN1
(Z)-1,2-Diphenylethene SCHEMBL22712863 0.96 MAOB (0.73) MAOBNFE2L2CYP19A1MAOAMEN1
(Z)-1,2-Diphenylethene SCHEMBL9134296 0.96 MAOB (0.73) MAOBNFE2L2CYP19A1MAOAMEN1
(Z)-1,2-Diphenylethene SCHEMBL9488270 0.96 MAOB (0.73) MAOBNFE2L2CYP19A1MAOAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4017526-A CATALYSTS FOR DIMERIZATION AND TRIMERIZATION OF CONJUGATED DIOLEFINS STUDIENGESELLSCHAFT KOHLE M.B.H. (DT) 1977-04-12 US claimed
US-7247687-B2 Late transition metal catalysts for olefin polymerization and oligomerization EXXONMOBIL CHEMICAL PATENTS INC. (US) 2007-07-24 US disclosed
EP-1521758-B1 LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION EXXONMOBIL CHEM PATENTS INC (US) 2006-05-24 EP disclosed
US-20060047094-A1 Late transition metal catalysts for olefin polymerization and oligomerization EXXONMOBIL CHEMICAL PATENTS INC. 2006-03-02 US disclosed
EP-1521758-A1 LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION Exxonmobil Chemical Patents Inc. (US) 2005-04-13 EP disclosed
WO-2004007509-A1 LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION EXXONMOBIL CHEMICAL PATENTS INC. (US) 2004-01-22 WO disclosed
US-RE29504-E Unsaturated hydrocarbons polymerization catalysts containing transition metal complexes and Bronsted acids INSTITUT FRANCAIS DU PETROLE, DES CARBURANTS ET LUBRIFIANTS (FR) 1977-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060047094-A1 Late transition metal catalysts for olefin polymerization and oligomerization MLX, LOX, LMTK3 MAOB 359/4885NFE2L2 111/4885CYP19A1 1837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.